An American Journal of Managed Care Forum: Bridging Evidence and Access in Advanced Small Cell Lung Cancer

Program Description

Small cell lung cancer (SCLC) is an aggressive and fast-growing type of lung cancer with a tendency for early, widespread metastasis. Around two-thirds of patients are diagnosed with extensive-stage SCLC (ES-SCLC), which involves distant metastases. Despite its aggressive nature, SCLC is initially sensitive to chemotherapy and radiation, yet patients often experience a high rate of relapse, underscoring the critical need for effective second-line and subsequent therapies. In this panel discussion, faculty will provide an in-depth, guideline-driven review of current standards and emerging treatment options for ES-SCLC, with a focus on addressing key challenges and gaps in care. The discussion will center on recent clinical data updates for novel agents and the evolving role of biomarkers in guiding treatment selection. Real-world operational and managed care strategies vital for optimizing patient outcomes, including facilitating timely access to care, enhancing medication coordination, navigating site-of-care considerations for novel therapies, and the essential role of managed care in preparing formularies and clinical pathways for rapid integration of new approvals, will be addressed.

Target Audience: Managed Care Pharmacist, Oncology Pharmacist

Type of Activity: Application
Release date: December 19, 2025
Expiration date: December 19, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Examine evolving treatment paradigms and updated clinical guidance for extensive-stage small cell lung cancer (ES-SCLC), with a focus on therapeutic sequencing beyond the first line
2. Interpret emerging clinical data on novel and investigational therapies for advanced SCLC, including mechanisms of action, safety profiles, and potential integration into care pathways
3. Apply managed care strategies to support timely access to evidence-based ES-SCLC therapies, addressing operational barriers and promoting equitable care delivery

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-416-H01-P. The activity is available for CE credit through December 19, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Kevin Chen, PharmD, MS, BCOP, CPP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Johnson & Johnson, Pfizer, Bristol Myers Squibb, Amgen, Daiichi Sankyo, Merck

Amanda S. Cass, PharmD, BCPS, BCOPhas the following relevant financial relationships with ineligible companies to disclose:

Consultant: G1 Therapeutics Inc, Takeda, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company, Limited

Abby Kim, PharmD, BCOP has the following relevant financial relationships with ineligible companies to disclose:

Employee of PBM: Prime Therapeutics Clinical Oncology Pharmacist Senior Principal Perform strategy and innovation to develop clinical solutions and products to service patients and clients

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Darren Luon, PharmD, BCOP

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms